Details
Stereochemistry | ACHIRAL |
Molecular Formula | C36H38F4N4O2S |
Molecular Weight | 666.771 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(F)C=C5
InChI
InChIKey=WDPFJWLDPVQCAJ-UHFFFAOYSA-N
InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3
Molecular Formula | C36H38F4N4O2S |
Molecular Weight | 666.771 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15957087Curator's Comment: description was created based on several sources, including
http://www.fiercebiotech.com/r-d/updated-glaxosmithkline-loses-its-first-big-phiii-bet-on-heart-drug-darapladib
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15957087
Curator's Comment: description was created based on several sources, including
http://www.fiercebiotech.com/r-d/updated-glaxosmithkline-loses-its-first-big-phiii-bet-on-heart-drug-darapladib
Darapladib (SB-435495), as reversible inhibitors of lipoprotein-associated phospholipase A(2) (Lp-PLA(2) has been developed and studies for the potential treatment of atherosclerosis. In November 2013, GSK announced that the drug had failed to meet Phase III endpoints in a trial of 16,000 patients with acute coronary syndrome.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3514 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12643913 |
0.25 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26465780 |
160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DARAPLADIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
17.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26465780 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
DARAPLADIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
519 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26465780 |
160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DARAPLADIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
645 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26465780 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
DARAPLADIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
116 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26465780 |
160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DARAPLADIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
39.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26465780 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
DARAPLADIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
160 mg 1 times / day multiple, oral Studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: Page: p.10 |
healthy, ADULT n = 24 Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FED Population Size: 24 Sources: Page: p.10 |
PubMed
Title | Date | PubMed |
---|---|---|
Gateways to clinical trials. | 2006 Sep |
|
Gateways to clinical trials. July-August 2008. | 2008 Jul-Aug |
|
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. | 2008 Oct |
|
Low and high density lipoprotein--cholesterol and coronary atherothrombosis. | 2009 |
|
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. | 2009 Oct |
|
Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities. | 2010 |
|
Lp-PLA2: A new target for statin therapy. | 2010 Jan |
|
Impact of analyzing less image frames per segment for radiofrequency-based volumetric intravascular ultrasound measurements in mild-to-moderate coronary atherosclerosis. | 2010 Jun |
|
Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. | 2010 Mar |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:51:33 UTC 2023
by
admin
on
Sat Dec 16 15:51:33 UTC 2023
|
Record UNII |
UI1U1MYH09
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29703
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
UI1U1MYH09
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
SUB32277
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
C529040
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
356057-34-6
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
8703
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
m4094
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | Merck Index | ||
|
Darapladib
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
RR-57
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
100000124361
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
CHEMBL204021
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
9939609
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
C72985
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
DTXSID70189073
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY | |||
|
DB06311
Created by
admin on Sat Dec 16 15:51:33 UTC 2023 , Edited by admin on Sat Dec 16 15:51:33 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|